Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
Should CYP2C19 genotype testing be performed in patients presenting with ISR on Plavix?
Related Questions
Do you prefer the routine use of bivalirudin over UFH during PCI cases in patients presenting with ACS?
What is your preferred intervention for diffuse severe ISR involving two layers of stent?
What is your stepwise approach to managing no re-flow during PCI?
During a coronary intervention, if the activated clotting time (ACT) is not within the therapeutic range despite administering weight-based unfractionated heparin, what alternative options do you consider?
For patients presenting with suspected type 1 NSTEMI and atrial fibrillation on anticoagulation, do you favor triple therapy or SAPT with systemic anticoagulation instead while awaiting LHC?
How do you manage anticoagulation/antiplatelet therapies with strong indications for uninterrupted therapy in setting of urgent procedures?
Would acute-onset thrombocytopenia and concern for active bleeding with platelet count below 50,000 prompt you to hold plavix and/or aspirin following PCI that was done 1-2 weeks ago?
What has been your approach to minimizing the risk of vascular complications when placing Impella support devices?
What are your preferred guide catheters to use for engaging coronaries in patients with mechanical or bioprosthetic aortic valves?
Do you avoid high-potency P2Y12 inhibitors in favor of clopidogrel in patients with atrial fibrillation on a DOAC who undergo PCI?
